查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971150

非酒精性脂肪性肝炎 (NASH) 市场分析及预测（至 2035 年）：按类型、产品类型、服务、技术、应用、最终用户、阶段、模式、组件、解决方案划分

Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Stage, Mode, Component, Solutions
出版日期: | 出版商: Global Insight Services | 英文 401 Pages | 商品交期: 3-5个工作天内

价格
简介目录

非酒精性脂肪性肝炎 (NASH) 市场预计将从 2024 年的 83.6 亿美元成长至 2034 年的 1,112.6 亿美元，复合年增长率约为 29.5%。 NASH 市场涵盖针对脂肪堆积引起的肝臟发炎和损伤的治疗方法，但不包括酒精相关原因。肥胖和糖尿病发病率的上升推动了这个快速成长的细分市场，促使研发部门对新型药物（例如 FXR促效剂和抗纤维化药物）进行大量投资。随着人们对 NASH 的认识不断提高以及诊断技术的进步，该市场呈现出成长势头，为药物创新提供了盈利的机会。

由于人们对肝臟相关疾病的认识不断提高，非酒精性脂肪性肝炎 (NASH) 市场预计将迎来显着成长。在治疗领域，药物细分市场成长最为迅猛，其中以抗纤维化和代谢药物为主的治疗方法展现出良好的疗效。 FXR促效剂和 PPAR促效剂等创新药物类别备受关注，反映了它们在疾病发病机制方面的潜力。诊断领域也呈现强劲成长，其中非侵入性检测因其对患者的友善性和准确性主导。在各种诊断方法中，弹性成像等能够精确评估肝纤维化的成像技术已成为第二大细分市场。对早期检测和个人化医疗的日益重视正在推动生物标记发现的进步。主要产业参与者之间的联合研究倡议和策略联盟正在加速创新。随着市场的不断发展，数位健康技术的整合有望改善患者管理和治疗依从性。

市场区隔
类型 治疗和诊断药物
产品 药品、生物製药和营养补充剂
服务 临床试验、咨询服务和监管服务
科技 生物技术、基因组学和蛋白​​质组学
应用 切片检查、影像学技术和生物标记检测
最终用户 医院、研究机构、製药公司
步 临床前研究、I期临床试验、II期临床试验、III期临床试验
实施例 侵入性、非侵入性
成分 活性成分、添加剂
治疗方法 生活型态改变、药物治疗与外科手术

市场概况：

非酒精性脂肪性肝炎 (NASH) 市场正经历市场份额、定价策略和新产品上市方面的动态变化。主要製药公司正策略性地强化产品系列，以获取更大的市场份额。价格竞争仍然激烈，并受到不断涌入市场的创新治疗方案的影响。研发的进步推动着新产品的频繁上市。这些创新旨在满足未被满足的医疗需求，并提供有前景的治疗方案。该市场的特点是拥有强大的药物研发管线，其中包括多个处于后期临床试验阶段的候选药物。 NASH 市场竞争异常激烈，主要参与者都在争夺主导。基准研究表明，策略联盟和伙伴关係关係至关重要。监管的影响也至关重要，北美和欧洲的监管机构制定了严格的指导方针，塑造市场动态。获得监管部门的核准是影响市场准入和扩张的关键里程碑。不断变化的医疗保健政策会影响药品定价和报销，这进一步加剧了竞争格局的复杂性。

主要趋势和驱动因素：

非酒精性脂肪性肝炎 (NASH) 市场正经历显着成长，其主要驱动因素是肥胖和糖尿病盛行率的不断上升。这些疾病是 NASH 的主要风险因素，并导致全球发病率不断攀升。诊断技术的进步是关键趋势，使得 NASH 的早期准确检测成为可能。这一点至关重要，因为早期介入可以显着改变疾病进展和患者预后。製药公司正大力投资研发，以发现有效的治疗方法。开发平臺十分强大，众多药物正处于不同的临床试验阶段。研发活动的活性化是市场扩张的关键驱动力。此外，生技公司与学术机构之间的合作也不断加强，促进了创新并加速了药物研发进程。肝臟健康和 NASH 的宣传活动日益受到关注，有助于提高诊断率。同时，人们也越来越重视将生活方式介入纳入综合治疗方案。在医疗基础设施不断完善、先进诊断技术普及程度不断提高的发展中地区，存在着许多机会。能够提供经济高效且扩充性解决方案的公司将在这些新兴市场中获得竞争优势。

限制与挑战：

非酒精性脂肪性肝炎 (NASH) 市场面临许多重大限制和挑战。其中一项主要挑战是 NASH 诊断的复杂性，通常需要进行侵入性肝臟切片检查，这阻碍了广泛筛检和早期发现。此外，对此疾病病理生理机制的了解有限，也使得标靶治疗的研发更加复杂，并延长了药物核准流程。缺乏有效的生物标记也为市场带来挑战，导致难以监测疾病进展和治疗效果。此外，潜在治疗方法的高成本可能会限制患者获得治疗的机会，并阻碍市场扩张，尤其是在中低收入国家。监管障碍也是一大挑战，严格的核准流程和国际监管差异可能会延缓新治疗方法的推广应用。最后，来自替代疗法和生活方式干预措施的竞争也构成威胁，因为患者和医疗服务提供者可能会选择成本更低或侵入性更小的治疗方案。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 治疗药物
    • 诊断试剂
  • 市场规模及预测：依产品划分
    • 製药
    • 生物製药
    • 营养保健品
  • 市场规模及预测：依服务划分
    • 临床试验
    • 咨询服务
    • 监管服务
  • 市场规模及预测：依技术划分
    • 生物技术
    • 基因组学
    • 蛋白质体学
  • 市场规模及预测：依应用领域划分
    • 切片检查
    • 诊断影像技术
    • 生物标记检测
  • 市场规模及预测：依最终用户划分
    • 医院
    • 研究所
    • 製药公司
  • 市场规模及预测：依阶段划分
    • 临床前
    • 第一阶段
    • II 期研究
    • III期临床试验
  • 市场规模及预测：按模式
    • 侵入性检查
    • 非侵入性
  • 市场规模及预测：依组件划分
    • 原料药
    • 添加剂
  • 市场规模及预测：按解决方案划分
    • 生活方式改善
    • 药物治疗
    • 手术介入

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Intercept Pharmaceuticals
  • Genfit
  • Madrigal Pharmaceuticals
  • Galmed Pharmaceuticals
  • Viking Therapeutics
  • Akero Therapeutics
  • Terns Pharmaceuticals
  • 89bio
  • Enyo Pharma
  • Inventiva
  • NorthSea Therapeutics
  • NGM Biopharmaceuticals
  • Gilead Sciences
  • Allergan
  • Conatus Pharmaceuticals
  • Zydus Cadila
  • Hepion Pharmaceuticals
  • Galectin Therapeutics
  • Alnylam Pharmaceuticals
  • Dicerna Pharmaceuticals

第九章：关于我们

简介目录
Product Code: GIS33177

Non-Alcoholic Steatohepatitis (NASH) Market is anticipated to expand from $8.36 billion in 2024 to $111.26 billion by 2034, growing at a CAGR of approximately 29.5%. The Non-Alcoholic Steatohepatitis (NASH) Market encompasses therapeutics targeting liver inflammation and damage due to fat accumulation, excluding alcohol-related causes. This burgeoning sector is driven by rising obesity and diabetes rates, with significant R&D investment in novel drug classes like FXR agonists and anti-fibrotic agents. The market is poised for growth as awareness and diagnostic advancements increase, offering lucrative opportunities for pharmaceutical innovation.

The Non-Alcoholic Steatohepatitis (NASH) Market is poised for significant growth, driven by rising awareness and increasing incidence of liver-related disorders. Within the treatment segment, the pharmaceuticals sub-segment is the top performer, with a focus on anti-fibrotic and metabolic drugs showing promising therapeutic outcomes. Innovative drug classes such as FXR agonists and PPAR agonists are gaining traction, reflecting their potential in addressing disease pathology. The diagnostics segment is also witnessing robust growth, with non-invasive tests leading due to their patient-friendly nature and accuracy. Among diagnostics, imaging techniques like elastography are emerging as the second highest performing sub-segment, offering precise liver fibrosis assessment. The growing emphasis on early detection and personalized medicine is fostering advancements in biomarker discovery. Collaborative research initiatives and strategic partnerships among key industry players are accelerating innovation. As the market evolves, the integration of digital health technologies is expected to enhance patient management and treatment adherence.

Market Segmentation
TypeTherapeutics, Diagnostics
ProductPharmaceuticals, Biologics, Nutraceuticals
ServicesClinical Trials, Consulting Services, Regulatory Services
TechnologyBiotechnology, Genomics, Proteomics
ApplicationLiver Biopsy, Imaging Techniques, Biomarker Assays
End UserHospitals, Research Institutes, Pharmaceutical Companies
StagePreclinical, Phase I, Phase II, Phase III
ModeInvasive, Non-Invasive
ComponentActive Pharmaceutical Ingredients, Excipients
SolutionsLifestyle Modification, Pharmacotherapy, Surgical Intervention

Market Snapshot:

The Non-Alcoholic Steatohepatitis (NASH) market is witnessing dynamic shifts in market share, pricing strategies, and new product launches. Leading pharmaceutical companies are strategically enhancing their portfolios to capture greater market share. Pricing remains competitive, influenced by innovative treatment options entering the market. New product launches are frequent, driven by advancements in research and development. These innovations aim to address unmet clinical needs, offering promising therapeutic solutions. The market is characterized by a robust pipeline of drugs, with several candidates in advanced stages of clinical trials. Competition within the NASH market is intense, with key players vying for dominance. Benchmarking reveals a landscape where strategic collaborations and partnerships are pivotal. Regulatory influences play a crucial role, with agencies in North America and Europe setting stringent guidelines that shape market dynamics. Regulatory approvals are critical milestones that impact market entry and expansion. The competitive environment is further complicated by the need for compliance with evolving healthcare policies, which affect drug pricing and reimbursement.

Geographical Overview:

The Non-Alcoholic Steatohepatitis (NASH) market is witnessing notable growth across various regions, each showcasing unique opportunities. North America leads the market, driven by a high prevalence of obesity and diabetes, which are major risk factors for NASH. The region's advanced healthcare infrastructure and strong focus on research and development further bolster its market position. Europe follows closely, with increasing awareness and early diagnosis initiatives contributing to market growth. The region's emphasis on innovative therapeutics and supportive regulatory frameworks enhances its appeal. In the Asia Pacific, the market is expanding rapidly, fueled by rising healthcare expenditure and a growing patient pool. Countries like China and India are emerging as key growth pockets due to increasing prevalence rates and improving healthcare access. Latin America and the Middle East & Africa present emerging opportunities. Latin America's market is driven by rising healthcare investments, while the Middle East & Africa are recognizing the significance of addressing NASH to mitigate associated healthcare burdens.

Key Trends and Drivers:

The Non-Alcoholic Steatohepatitis (NASH) market is experiencing substantial growth driven by increasing prevalence of obesity and diabetes. These conditions are major risk factors for NASH, leading to a rising incidence rate globally. Key trends include advancements in diagnostic technologies, enabling earlier and more accurate detection of NASH. This is crucial as early-stage intervention can significantly alter disease progression and patient outcomes. Pharmaceutical companies are investing heavily in research and development to discover effective therapeutic options. The pipeline is robust, with numerous drugs in various stages of clinical trials. This surge in R&D activity is a critical driver of market expansion. Additionally, there is a growing collaboration between biotech firms and academic institutions, fostering innovation and accelerating drug development timelines. Awareness campaigns about liver health and NASH are gaining traction, contributing to increased diagnosis rates. This is coupled with a greater emphasis on lifestyle modifications as part of comprehensive treatment plans. Opportunities abound in developing regions where healthcare infrastructure is improving, and access to advanced diagnostics is expanding. Companies that can provide cost-effective and scalable solutions stand to gain a competitive edge in these emerging markets.

Restraints and Challenges:

The Non-Alcoholic Steatohepatitis (NASH) market encounters several significant restraints and challenges. A primary challenge is the complexity of accurately diagnosing NASH, which often requires invasive liver biopsies that deter widespread screening and early detection. Additionally, there is a limited understanding of the disease's pathophysiology, complicating the development of targeted therapies and prolonging the drug approval process. The market also suffers from a lack of effective biomarkers, hindering the ability to monitor disease progression and treatment efficacy. Furthermore, the high cost of potential therapies may restrict access, especially in low- and middle-income countries, thus limiting market expansion. Regulatory hurdles present another challenge, as stringent approval processes and varying international regulations can delay the introduction of new treatments. Lastly, competition from alternative therapies and lifestyle interventions poses a threat, as patients and healthcare providers may opt for less costly or invasive options.

Key Players:

Intercept Pharmaceuticals, Genfit, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Viking Therapeutics, Akero Therapeutics, Terns Pharmaceuticals, 89bio, Enyo Pharma, Inventiva, NorthSea Therapeutics, NGM Biopharmaceuticals, Gilead Sciences, Allergan, Conatus Pharmaceuticals, Zydus Cadila, Hepion Pharmaceuticals, Galectin Therapeutics, Alnylam Pharmaceuticals, Dicerna Pharmaceuticals

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Stage
  • 2.8 Key Market Highlights by Mode
  • 2.9 Key Market Highlights by Component
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Therapeutics
    • 4.1.2 Diagnostics
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Pharmaceuticals
    • 4.2.2 Biologics
    • 4.2.3 Nutraceuticals
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Clinical Trials
    • 4.3.2 Consulting Services
    • 4.3.3 Regulatory Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Biotechnology
    • 4.4.2 Genomics
    • 4.4.3 Proteomics
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Liver Biopsy
    • 4.5.2 Imaging Techniques
    • 4.5.3 Biomarker Assays
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Research Institutes
    • 4.6.3 Pharmaceutical Companies
  • 4.7 Market Size & Forecast by Stage (2020-2035)
    • 4.7.1 Preclinical
    • 4.7.2 Phase I
    • 4.7.3 Phase II
    • 4.7.4 Phase III
  • 4.8 Market Size & Forecast by Mode (2020-2035)
    • 4.8.1 Invasive
    • 4.8.2 Non-Invasive
  • 4.9 Market Size & Forecast by Component (2020-2035)
    • 4.9.1 Active Pharmaceutical Ingredients
    • 4.9.2 Excipients
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Lifestyle Modification
    • 4.10.2 Pharmacotherapy
    • 4.10.3 Surgical Intervention

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Stage
      • 5.2.1.8 Mode
      • 5.2.1.9 Component
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Stage
      • 5.2.2.8 Mode
      • 5.2.2.9 Component
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Stage
      • 5.2.3.8 Mode
      • 5.2.3.9 Component
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Stage
      • 5.3.1.8 Mode
      • 5.3.1.9 Component
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Stage
      • 5.3.2.8 Mode
      • 5.3.2.9 Component
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Stage
      • 5.3.3.8 Mode
      • 5.3.3.9 Component
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Stage
      • 5.4.1.8 Mode
      • 5.4.1.9 Component
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Stage
      • 5.4.2.8 Mode
      • 5.4.2.9 Component
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Stage
      • 5.4.3.8 Mode
      • 5.4.3.9 Component
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Stage
      • 5.4.4.8 Mode
      • 5.4.4.9 Component
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Stage
      • 5.4.5.8 Mode
      • 5.4.5.9 Component
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Stage
      • 5.4.6.8 Mode
      • 5.4.6.9 Component
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Stage
      • 5.4.7.8 Mode
      • 5.4.7.9 Component
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Stage
      • 5.5.1.8 Mode
      • 5.5.1.9 Component
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Stage
      • 5.5.2.8 Mode
      • 5.5.2.9 Component
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Stage
      • 5.5.3.8 Mode
      • 5.5.3.9 Component
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Stage
      • 5.5.4.8 Mode
      • 5.5.4.9 Component
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Stage
      • 5.5.5.8 Mode
      • 5.5.5.9 Component
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Stage
      • 5.5.6.8 Mode
      • 5.5.6.9 Component
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Stage
      • 5.6.1.8 Mode
      • 5.6.1.9 Component
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Stage
      • 5.6.2.8 Mode
      • 5.6.2.9 Component
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Stage
      • 5.6.3.8 Mode
      • 5.6.3.9 Component
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Stage
      • 5.6.4.8 Mode
      • 5.6.4.9 Component
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Stage
      • 5.6.5.8 Mode
      • 5.6.5.9 Component
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Intercept Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Genfit
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Madrigal Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Galmed Pharmaceuticals
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Viking Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Akero Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Terns Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 89bio
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Enyo Pharma
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Inventiva
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 NorthSea Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 NGM Biopharmaceuticals
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Gilead Sciences
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Allergan
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Conatus Pharmaceuticals
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Zydus Cadila
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Hepion Pharmaceuticals
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Galectin Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Alnylam Pharmaceuticals
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Dicerna Pharmaceuticals
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us